These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35155791)

  • 1. Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma.
    Arron ST; Wysong A; Hall MA; Bailey CN; Covington KR; Kurley SJ; Goldberg MS; Kasprzak JM; Somani AK; Ibrahim SF; Brodland DG; Cleaver NJ; Maher IA; Xia Y; Koyfman SA; Newman JG
    Laryngoscope Investig Otolaryngol; 2022 Feb; 7(1):135-144. PubMed ID: 35155791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prognostic Value and Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test in Cutaneous Squamous Cell Carcinoma: Systematic Review and Meta-Analysis.
    Masarwy R; Shilo S; Carmel Neiderman NN; Kampel L; Horowitz G; Muhanna N; Mansour J
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
    Wysong A; Somani AK; Ibrahim SF; Cañueto J; Fitzgerald AL; Siegel JJ; Prasai A; Goldberg MS; Farberg AS; Regula C; Bar A; Kasprzak J; Brodland DG; Koyfman SA; Arron ST
    Dermatol Ther (Heidelb); 2024 Mar; 14(3):593-612. PubMed ID: 38424384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma.
    Wysong A; Newman JG; Covington KR; Kurley SJ; Ibrahim SF; Farberg AS; Bar A; Cleaver NJ; Somani AK; Panther D; Brodland DG; Zitelli J; Toyohara J; Maher IA; Xia Y; Bibee K; Griego R; Rigel DS; Meldi Plasseraud K; Estrada S; Sholl LM; Johnson C; Cook RW; Schmults CD; Arron ST
    J Am Acad Dermatol; 2021 Feb; 84(2):361-369. PubMed ID: 32344066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management.
    Farberg AS; Hall MA; Douglas L; Covington KR; Kurley SJ; Cook RW; Dinehart SM
    Curr Med Res Opin; 2020 Aug; 36(8):1301-1307. PubMed ID: 32351136
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test for Improved Patient Management Decisions and Disease-Related Outcomes when Combined with Current Clinicopathological Risk Factors for Cutaneous Squamous Cell Carcinoma (cSCC): Case Series.
    Au JH; Hooper PB; Fitzgerald AL; Somani AK
    Dermatol Ther (Heidelb); 2022 Feb; 12(2):591-597. PubMed ID: 34951694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating 40-GEP Testing to Improve Clinical Recommendations for Adjuvant Radiation for Cutaneous Squamous Cell Carcinoma: Multidisciplinary Consensus Guidelines.
    Gopal R; Marquardt M; Singh G; Tolkachjov SN; Arron ST
    J Clin Aesthet Dermatol; 2024 Mar; 17(3 Suppl 2):S3-S8. PubMed ID: 38495846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporation of the 40-Gene Expression Profile (40-GEP) Test to Improve Treatment Decisions in High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients: Case Series and Algorithm.
    Singh G; Tolkachjov SN; Farberg AS
    Clin Cosmet Investig Dermatol; 2023; 16():925-935. PubMed ID: 37051586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Gene Expression Profile Testing on the Management of Squamous Cell Carcinoma by Dermatologists.
    Rebeca T; Giselle P; Litchman GH; Rigel DS
    J Drugs Dermatol; 2019 Oct; 18(10):980-984. PubMed ID: 31584775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test.
    Ibrahim SF; Kasprzak JM; Hall MA; Fitzgerald AL; Siegel JJ; Kurley SJ; Covington KR; Goldberg MS; Farberg AS; Trotter SC; Reed K; Brodland DG; Koyfman SA; Somani AK; Arron ST; Wysong A
    Future Oncol; 2022 Mar; 18(7):833-847. PubMed ID: 34821148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of a 40-Gene Expression Profile With Risk of Metastatic Disease Progression of Cutaneous Squamous Cell Carcinoma and Specification of Benefit of Adjuvant Radiation Therapy.
    Arron ST; Cañueto J; Siegel J; Fitzgerald A; Prasai A; Koyfman SA; Yom SS
    Int J Radiat Oncol Biol Phys; 2024 Nov; 120(3):760-771. PubMed ID: 38810706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 40-Gene Expression Profile Representative of Metastatic Risk of Squamous Cell Carcinoma in a Mohs Surgical Patient.
    Slater KN; Ryder E; Gomez-Meade C
    Cureus; 2023 Oct; 15(10):e46853. PubMed ID: 37954812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma.
    Litchman GH; Fitzgerald AL; Kurley SJ; Cook RW; Rigel DS
    Curr Med Res Opin; 2020 Aug; 36(8):1295-1300. PubMed ID: 32372702
    [No Abstract]   [Full Text] [Related]  

  • 14. Validating 4 Staging Systems for Cutaneous Squamous Cell Carcinoma Using Population-Based Data: A Nested Case-Control Study.
    Roscher I; Falk RS; Vos L; Clausen OPF; Helsing P; Gjersvik P; Robsahm TE
    JAMA Dermatol; 2018 Apr; 154(4):428-434. PubMed ID: 29516080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of four cutaneous squamous cell carcinoma staging systems using nationwide data.
    Venables ZC; Tokez S; Hollestein LM; Mooyaart AL; van den Bos RR; Rous B; Leigh IM; Nijsten T; Wakkee M
    Br J Dermatol; 2022 May; 186(5):835-842. PubMed ID: 34862598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting adjuvant radiation therapy benefit in cutaneous squamous cell carcinoma with the 40-gene expression profile.
    Ruiz ES; Brito K; Karn EE; Vidimos AT; Campbell SR; Wang DM; Siegel JJ; Covington KR; Cook RW; Goldberg MS; Koyfman SA
    Future Oncol; 2024; 20(35):2737-2746. PubMed ID: 39229801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
    Hooper PB; Farberg AS; Fitzgerald AL; Siegel JJ; Rackley BB; Prasai A; Kurley SJ; Goldberg MS; Litchman GH
    Cancer Invest; 2022 Nov; 40(10):911-922. PubMed ID: 36073945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalised decision making to predict absolute metastatic risk in cutaneous squamous cell carcinoma: development and validation of a clinico-pathological model.
    Rentroia-Pacheco B; Tokez S; Bramer EM; Venables ZC; van de Werken HJG; Bellomo D; van Klaveren D; Mooyaart AL; Hollestein LM; Wakkee M
    EClinicalMedicine; 2023 Sep; 63():102150. PubMed ID: 37662519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of selected risk factors for nodal metastases in head and neck cutaneous squamous cell carcinoma.
    Szewczyk M; Pazdrowski J; Golusiński P; Dańczak-Pazdrowska A; Marszałek S; Golusiński W
    Eur Arch Otorhinolaryngol; 2015 Oct; 272(10):3007-12. PubMed ID: 25217080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging.
    Wisco OJ; Marson JW; Litchman GH; Brownstone N; Covington KR; Martin BJ; Quick AP; Siegel JJ; Caruso HG; Cook RW; Winkelmann RR; Rigel DS
    Melanoma Res; 2022 Apr; 32(2):98-102. PubMed ID: 35254332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.